Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05904496 · ClinicalTrials.gov registry record · Phase 1
A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by BeiGene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT05904496 is a Phase 1 study that was terminated before completion, run by BeiGene. The registered enrollment target is 44 participants.
The verdict
NCT05904496, a Phase 1 study, was terminated before completion, sponsored by BeiGene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is a First in Human (FIH) Phase 1, multicenter, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-30813 as monotherapy or in combination with tislelizumab in participants with advanced or metastatic solid tumors. The study will be conducted in 2 parts: Phase 1a dose escalation and Phase 1b dose expansion.
Interventions
- DRUG Tislelizumab
- DRUG BGB-30813
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2023-07-19 |
| Est. Completion | 2025-08-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05904496
The ClinicalTrials.gov registry entry for NCT05904496 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tislelizumab is the first listed.
NCT05904496 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05904496 about?
NCT05904496 is a clinical study titled "A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors". This is a First in Human (FIH) Phase 1, multicenter, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-30813 as monotherapy or in combination with tislelizumab in participants with ...
What is the current status of trial NCT05904496?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2023-07-19. Estimated completion is 2025-08-20.
What interventions are being tested in trial NCT05904496?
The interventions under investigation include: Tislelizumab (DRUG), BGB-30813 (DRUG).
Who is sponsoring clinical trial NCT05904496?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.